Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)

Exclusion Criteria

• •Subjects who are unwilling or unable to provide a signed informed consent form;
• •Any contraindication to the treatment with the SPC of amlodipine/atorvastatin/perindopril according to its' approved instruction for medical use in the Russian Federation;
• •Concomitant use of any other ACE inhibitors, CCBs, ARBs and statins.
• •Supposed low treatment adherence to the assigned SPC and the risk for poor collaboration between the patient and the investigator during the study;
• •Any severe, decompensated or unstable somatic diseases or states that according to investigator discretion are life-threatening or worsen the prognosis for the patient: myocardial infarction in the past 3 months, unstable angina, current decompensation of diabetes mellitus, autoimmune or oncological diseases, severe cardiac arrhythmia, gastrointestinal disorders affecting absorbtion, severe hepatic diseases, pancreatic diseases, severe allergic reactions, connective tissue diseases etc;
• •Secondary arterial hypertension;
• •Alcohol or any drug abuse;
• •Surgical intervention on heart or coronary vessels (i.e., heart valve(s) replacement, stent implantation or CABG), or any non-cardiological serious surgical intervention that are planned within next 3 months and may require withdrawal or changes in current therapy;
• •Glomerular filtration rate less than 60 ml/min/1,72m2;
• •Participating in any other clinical trial currently or during 30 days period before informed consent was signed.